Short answer
Protagonist Therapeutics, Inc (PTGX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter 2026 financial results for period ended September 30, 2026.
Protagonist Therapeutics, Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter 2026 financial results for period ended September 30, 2026
- Corporate update announced alongside quarterly results
- Full financial figures and operating details in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- MIMRYLO FDA approval triggered $275 million in Takeda payments, materially strengthening near-term liquidity and validating the partnered-asset strategy
- Cash, equivalents and marketable securities reached $834.6 million, supporting pipeline investment and the authorized $300 million share repurchase
- Third-quarter revenue $274.4 million and net income $220.0 million, versus revenue $4.7 million and net loss $39.3 million in 2025
- Takeda royalties range 14% to 29%, while ICOTYDE royalties range 6% to 10%, creating growing recurring revenue exposure beyond milestones
- PN-881 Phase 2b psoriasis study planned for early Q1 2027, with additional oral obesity and polycythemia vera programs advancing toward clinical development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protagonist Therapeutics, Inc 8-K filings
Get the next PTGX 8-K as it lands
Follow PTGX for push alerts, or ask the research agent what this filing means.